Integrium is a full-service Clinical Proof of Concept (PoC) Firm focused within the therapeutic areas of Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Regenerative, and Orphan Disease. Although we have the scientific, medical, operational, and regulatory expertise to cover all stages of clinical development (Phase I-IV), we are Experts in the Strategy, Design and Execution of Clinical PoC Trials.
Because we understand the complexities and nuances of clinical research in the Cardiovascular disease, Metabolic disease, Renal disease, Inflammatory disease, Dermatology, Wound Healing, Regenerative, and Orphan Disease areas, Integrium delivers successful, engineered clinical study solutions to biopharmaceutical companies. We help design scientifically rigorous, yet feasible studies. We know reliable, high-quality, productive investigators and work well with them. We know where and how to get the needed patients for a particular study. We provide study teams with experience levels far above industry norms that know how to work seamlessly and efficiently with our clients, and achieve or beat timelines.
Integrium’s client base is diverse, consisting of specialty, small, mid-size, and large companies. We have solid, long-term working relationships characterized by high repeat business rates with many of our clients. Our engagements have ranged from those consisting of highly customized, comprehensive management services for a multi-study program to functional-level support for an individual trial. Integrium has the flexibility and breadth required to serve a wide array of clinical development needs for its biopharmaceutical company clients.
Integrium provides its clients with unparalleled service. Our employees are deeply committed to client satisfaction. We take a highly collaborative, partnering approach when working with our clients. Taking the extra steps that are frequently required to deliver outstanding performance is part of our corporate culture. Our executive management team is readily accessible to clients. In fact, we assign one or more executive managers to each study team to provide therapeutic and operational support to the client and members of the Integrium team.
Integrium was founded in 1998 by clinical research thought leaders who wanted to build a CRO based on therapeutic focus and excellence. These individuals continue to lead the company today. We have offices in North America, and formal alliances with partner CROs regionally and in Europe, Australia, and India. Integrium is privately owned.